IBRX ImmunityBio, Inc.
IBRX ImmunityBio, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 neutral converging
POC $2.17 · VWAP $6.22 · +27.3% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
IBRX Price Structure
Loading timeframes…
Peers
Every watchlist IBRX belongs to, members best 30-day change first — IBRX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@ibb
Reported the quarter ending 2026-03-31: revenue $44M, diluted EPS $-0.62, net income $-633M (SEC filing). Across the print the stock moved -4.6% (close before → first close after).
full note →Against street estimates
How IBRX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about IBRX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- ImmunityBio (IBRX) Earnings Date and Reports 2026
- ImmunityBio (IBRX) 10K Form and Latest SEC Filings 2026
- IBRX News Today | Why did ImmunityBio stock go up today?
- IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
- ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline
IBRX research tape
26 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.